Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Medicines Co.’s Angiox Heart Drug Wins U.K. Cost Agency Approval

July 27 (Bloomberg) -- Medicines Co.’s Angiox can be given to adults who suffer a form of heart attack known as an ST-segment elevation myocardial infarction, or STEMI, the U.K.’s medical-cost regulator said.

Angiox can be given with aspirin and clopidogrel to STEMI patients who are undergoing primary percutaneous coronary intervention, the National Institute for Health and Clinical Excellence said in guidelines published today. The agency, also known as NICE, rules on which treatments the U.K.’s National Health Service will fund.

To contact the reporter on this story: Andrea Gerlin in London at

To contact the editor responsible for this story: Phil Serafino at

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.